Risk factors
Tenax Therapeutics (TENX) risk factors
Item 1A of every Tenax Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors46 risks2 new2 dropped11 reworded
Net operating losses surged from $19.5 million to $56.4 million, driving increased reliance on equity financing and share dilution.
Filed Mar 10, 2026 - FY2024 10-K risk factors46 risks
Tenax Therapeutics relies heavily on the clinical and commercial success of levosimendan for PH-HFpEF and imatinib for PAH. The company has a history of net operating losses, totaling $19.5 million in 2024, and operates with a very small team of just four full-time employees. Manufacturing is outsourced entirely to third parties, including Orion for levosimendan supply.
Filed Mar 25, 2025